BDNF and Anxiety: It is, however, entirely possible that the effects of TSA co-treatment on anxiety-like phenotypes are not only due to increased Bdnf expression, especially since Bdnf expression levels do not significantly differ between MS-275, NaB, or TSA co-treated mice (see Fig.2c), and that the anxiolytic effects triggered by TSA/fluoxetine co-treatment are also mediated by changes in expression of other (yet to be identified) genes that play a role in the expression of anxiety-related phenotypes and whose expression is modulated by the HDACs targeted by TSA.